| Pieter J Vreede, MD | |
|
355 Westfield Rd, Noblesville, IN 46060-1443 | |
| (317) 770-5861 | |
| (317) 770-5867 |
| Full Name | Pieter J Vreede |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 38 Years |
| Location | 355 Westfield Rd, Noblesville, Indiana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1417934647 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | 01036588 (Indiana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Rush Memorial Hospital | Rushville, IN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Rush Memorial Hospital | 7012802754 | 58 |
News Archive
People who live in green neighborhoods are less likely to develop cardiovascular disease, according to research presented at ESC Congress 2021.
Incyte Corporation, Results from a Phase I/II study of Incyte's janus kinase (JAK) inhibitor with the investigational name INCB18424 (also known as INCB018424 and INC424) were published today in The New England Journal of Medicine, demonstrating marked and durable clinical benefits in patients with myelofibrosis.
Advanced Biological Laboratories (ABL) S.A., a biomedical company engaged in the development and commercialization of personalized healthcare electronic medical record systems coupled with expert rules using decision support tools, is pleased to announce today that the Canadian Intellectual Property Office has issued a Notice of Allowance and the Patent Office of India has issued a new patent for our patent applications derived from our U.S. Patent Nos. 6,081,786 and 6,188,988 to Barry et al.
PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has received a Phase 2 grant in the amount of $986,000 from the National Institute of Health (NIH) to support the development of defensin mimetic antimicrobial compounds for the treatment of oral candidiasis. This grant will fund this research project through August 31, 2012. This award represents the 14th grant or research contract received to date by PolyMedix.
House Republicans are so bent on blocking any and all aspects of health care reform that they have passed a bill that would eliminate a farsighted program — the Prevention and Public Health Fund — intended to help states and communities prevent diseases. Eliminating the fund would save roughly $16 billion over the course of a decade. … The loss to states and local communities would be considerable.
› Verified 4 days ago
| Entity Name | Rush Memorial Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1497726020 PECOS PAC ID: 7012802754 Enrollment ID: O20040220000164 |
News Archive
People who live in green neighborhoods are less likely to develop cardiovascular disease, according to research presented at ESC Congress 2021.
Incyte Corporation, Results from a Phase I/II study of Incyte's janus kinase (JAK) inhibitor with the investigational name INCB18424 (also known as INCB018424 and INC424) were published today in The New England Journal of Medicine, demonstrating marked and durable clinical benefits in patients with myelofibrosis.
Advanced Biological Laboratories (ABL) S.A., a biomedical company engaged in the development and commercialization of personalized healthcare electronic medical record systems coupled with expert rules using decision support tools, is pleased to announce today that the Canadian Intellectual Property Office has issued a Notice of Allowance and the Patent Office of India has issued a new patent for our patent applications derived from our U.S. Patent Nos. 6,081,786 and 6,188,988 to Barry et al.
PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has received a Phase 2 grant in the amount of $986,000 from the National Institute of Health (NIH) to support the development of defensin mimetic antimicrobial compounds for the treatment of oral candidiasis. This grant will fund this research project through August 31, 2012. This award represents the 14th grant or research contract received to date by PolyMedix.
House Republicans are so bent on blocking any and all aspects of health care reform that they have passed a bill that would eliminate a farsighted program — the Prevention and Public Health Fund — intended to help states and communities prevent diseases. Eliminating the fund would save roughly $16 billion over the course of a decade. … The loss to states and local communities would be considerable.
› Verified 4 days ago
| Entity Name | Riverview Anesthesiologists Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1558552984 PECOS PAC ID: 9133173743 Enrollment ID: O20050308000083 |
News Archive
People who live in green neighborhoods are less likely to develop cardiovascular disease, according to research presented at ESC Congress 2021.
Incyte Corporation, Results from a Phase I/II study of Incyte's janus kinase (JAK) inhibitor with the investigational name INCB18424 (also known as INCB018424 and INC424) were published today in The New England Journal of Medicine, demonstrating marked and durable clinical benefits in patients with myelofibrosis.
Advanced Biological Laboratories (ABL) S.A., a biomedical company engaged in the development and commercialization of personalized healthcare electronic medical record systems coupled with expert rules using decision support tools, is pleased to announce today that the Canadian Intellectual Property Office has issued a Notice of Allowance and the Patent Office of India has issued a new patent for our patent applications derived from our U.S. Patent Nos. 6,081,786 and 6,188,988 to Barry et al.
PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has received a Phase 2 grant in the amount of $986,000 from the National Institute of Health (NIH) to support the development of defensin mimetic antimicrobial compounds for the treatment of oral candidiasis. This grant will fund this research project through August 31, 2012. This award represents the 14th grant or research contract received to date by PolyMedix.
House Republicans are so bent on blocking any and all aspects of health care reform that they have passed a bill that would eliminate a farsighted program — the Prevention and Public Health Fund — intended to help states and communities prevent diseases. Eliminating the fund would save roughly $16 billion over the course of a decade. … The loss to states and local communities would be considerable.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Pieter J Vreede, MD 1300 N Main St, Rushville, IN 46173-1116 Ph: (765) 932-4111 | Pieter J Vreede, MD 355 Westfield Rd, Noblesville, IN 46060-1443 Ph: (317) 770-5861 |
News Archive
People who live in green neighborhoods are less likely to develop cardiovascular disease, according to research presented at ESC Congress 2021.
Incyte Corporation, Results from a Phase I/II study of Incyte's janus kinase (JAK) inhibitor with the investigational name INCB18424 (also known as INCB018424 and INC424) were published today in The New England Journal of Medicine, demonstrating marked and durable clinical benefits in patients with myelofibrosis.
Advanced Biological Laboratories (ABL) S.A., a biomedical company engaged in the development and commercialization of personalized healthcare electronic medical record systems coupled with expert rules using decision support tools, is pleased to announce today that the Canadian Intellectual Property Office has issued a Notice of Allowance and the Patent Office of India has issued a new patent for our patent applications derived from our U.S. Patent Nos. 6,081,786 and 6,188,988 to Barry et al.
PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has received a Phase 2 grant in the amount of $986,000 from the National Institute of Health (NIH) to support the development of defensin mimetic antimicrobial compounds for the treatment of oral candidiasis. This grant will fund this research project through August 31, 2012. This award represents the 14th grant or research contract received to date by PolyMedix.
House Republicans are so bent on blocking any and all aspects of health care reform that they have passed a bill that would eliminate a farsighted program — the Prevention and Public Health Fund — intended to help states and communities prevent diseases. Eliminating the fund would save roughly $16 billion over the course of a decade. … The loss to states and local communities would be considerable.
› Verified 4 days ago
Carolyn Sue Lanter, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 9700 E 146th St, Noblesville, IN 46060 Phone: 317-567-2180 Fax: 317-567-2191 | |
Brian C Keys, D.O. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 355 Westfield Rd, Noblesville, IN 46060 Phone: 317-770-5861 Fax: 317-770-5867 | |
Matthew A Swift, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 355 Westfield Rd, Noblesville, IN 46060 Phone: 317-770-5861 Fax: 317-770-5867 | |
James A Crowe, M.D. Anesthesiology Medicare: Medicare Enrolled Practice Location: 355 Westfield Rd, Noblesville, IN 46060 Phone: 317-770-5861 Fax: 317-770-5867 | |
John Peter Klim, DO Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 18077 River Rd Ste 200, Noblesville, IN 46062 Phone: 317-776-7028 Fax: 317-773-7910 | |
Jason Paul Renschler, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 395 Westfield Rd, Noblesville, IN 46060 Phone: 317-770-2800 Fax: 317-870-0499 |